Novel vaccine protects mice against Staphylococcus aureus infection, say researchers
The novel vaccine 4X-SA-GP harnesses the anti-fungal immune response to provide immunity against Staphylococcus aureus (S. aureus) infection.
List view / Grid view
The novel vaccine 4X-SA-GP harnesses the anti-fungal immune response to provide immunity against Staphylococcus aureus (S. aureus) infection.
A study in older mice with type 2 diabetes revealed a tuberculosis vaccine elicited a strong immune response, making it a promising candidate for the condition.
Five immune response biomarkers have been identified by researchers who say they can be used to classify which COVID-19 patients will survive the disease.
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
Research has shown T cells taken from patients with COVID-19 target the same three to eight immunodominant epitopes - most of which are not on the Spike protein.
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
The novel aryl hydrocarbon receptor (AHR) inhibiting drug slowed zika virus replication and prevented mouse foetuses malforming in infected mothers.
Which immune cells contribute towards immune-induced neurodegeneration and how could this knowledge enable conditions such Alzheimer’s and multiple sclerosis to be treated?
A study of the SARS-CoV-2 nonstructural protein 1 (Nsp1) showed it can supress translation and inhibit anti-viral defence mechanisms, making it a potential target for drugs.
The newly identified hallmarks of critical COVID-19 indicate a combination of interferon supplementation and anti-inflammatory therapies could be effective in treating patients with severe COVID-19 symptoms.
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
Researchers reveal the Vav3 protein is responsible for the formation of bacterial docking stations in the airway cells which promote the recurrent lung infections seen in Cystic Fibrosis patients.
Scientists demonstrated that remdesivir can inhibit SARS-CoV-2 replication in human lung cells and improve lung function in mice with COVID-19.
Researchers reveal a reduction in the number of eosinophil immune cells in belly fat with age may be the underlying cause of many age-related conditions with chronic low-grade inflammation.